Arvinas, Inc. announces participation in four investor conferences, discussing innovative targeted protein degradation therapies.
Quiver AI Summary
Arvinas, Inc., a clinical-stage biotechnology company focused on targeted protein degradation, announced its participation in four upcoming investor conferences: TD Cowen, Leerink Global Healthcare, Barclays Global Healthcare, and the Jefferies Biotech Summit, scheduled from March 3 to March 11, 2026. At these events, the management will engage in fireside chats, with replays available on the company's website. Arvinas is dedicated to developing therapies through its PROTAC platform, which targets and degrades disease-causing proteins. The company is advancing several investigational drugs aimed at treating conditions such as neurodegenerative disorders, mutated cancers, non-Hodgkin Lymphoma, and breast cancer. Arvinas is based in New Haven, Connecticut.
Potential Positives
- Arvinas is actively engaging with investors by participating in multiple prominent healthcare conferences, demonstrating transparency and commitment to investor relations.
- The company is advancing multiple investigational drugs through clinical development, showcasing its potential for significant contributions to treating serious diseases.
- The usage of innovative PROTAC technology positions Arvinas at the forefront of drug development in biotechnology, highlighting its unique approach to addressing unmet medical needs.
Potential Negatives
- Participation in multiple investor conferences may indicate a need for greater investor engagement, suggesting that current interest or confidence in the company may not be as strong as desired.
- The focus on clinical-stage developments implies that Arvinas has not yet brought any products to market, which can be a significant risk factor for investors regarding the company's long-term viability and financial stability.
- The lack of updates on the progress or success of their investigational drugs could raise concerns about the feasibility and potential effectiveness of their pipeline, particularly in a highly competitive biotech industry.
FAQ
What upcoming investor conferences is Arvinas participating in?
Arvinas will participate in the TD Cowen Health Care Conference, Leerink Global Healthcare Conference, Barclays Global Healthcare Conference, and Jefferies Biotech Summit.
When is the fireside chat at the TD Cowen Conference?
The fireside chat at the TD Cowen Conference is scheduled for March 3, 2026, at 1:10 p.m. ET.
What is the focus of Arvinas as a biotechnology company?
Arvinas is focused on creating innovative therapies that use targeted protein degradation to treat debilitating diseases.
How can I access replays of the fireside chats?
Replays of the fireside chats will be available on the Events and Presentations section of Arvinas' website.
What investigational drugs is Arvinas currently developing?
Arvinas is developing several investigational drugs, including ARV-102, ARV-806, ARV-393, and vepdegestrant for various diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ARVN Insider Trading Activity
$ARVN insiders have traded $ARVN stock on the open market 7 times in the past 6 months. Of those trades, 1 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ARVN stock by insiders over the last 6 months:
- BRIGGS MORRISON purchased 30,000 shares for an estimated $227,010
- NOAH BERKOWITZ (Chief Medical Officer) sold 5,685 shares for an estimated $67,594
- ANDREW SAIK (Chief Financial Officer) sold 5,134 shares for an estimated $61,043
- ANGELA M CACACE (Chief Scientific Officer) sold 4,592 shares for an estimated $54,598
- RANDY TEEL (President and CEO) sold 4,403 shares for an estimated $52,351
- DAVID K LOOMIS (Chief Accounting Officer) has made 0 purchases and 2 sales selling 1,246 shares for an estimated $14,354.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ARVN Hedge Fund Activity
We have seen 100 institutional investors add shares of $ARVN stock to their portfolio, and 135 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LOGOS GLOBAL MANAGEMENT LP removed 5,575,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $66,119,500
- POINT72 ASSET MANAGEMENT, L.P. added 2,315,361 shares (+inf%) to their portfolio in Q4 2025, for an estimated $27,460,181
- CAPTION MANAGEMENT, LLC removed 1,343,029 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $11,442,607
- VANGUARD GROUP INC removed 1,331,629 shares (-15.6%) from their portfolio in Q4 2025, for an estimated $15,793,119
- TCG CROSSOVER MANAGEMENT, LLC added 1,048,851 shares (+64.8%) to their portfolio in Q4 2025, for an estimated $12,439,372
- TWO SIGMA INVESTMENTS, LP added 992,463 shares (+inf%) to their portfolio in Q4 2025, for an estimated $11,770,611
- OPALEYE MANAGEMENT INC. removed 987,818 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $11,715,521
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ARVN Analyst Ratings
Wall Street analysts have issued reports on $ARVN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stephens & Co. issued a "Overweight" rating on 11/10/2025
- BTIG issued a "Buy" rating on 09/18/2025
To track analyst ratings and price targets for $ARVN, check out Quiver Quantitative's $ARVN forecast page.
$ARVN Price Targets
Multiple analysts have issued price targets for $ARVN recently. We have seen 6 analysts offer price targets for $ARVN in the last 6 months, with a median target of $15.0.
Here are some recent targets:
- Yigal Nochomovitz from Citigroup set a target price of $15.0 on 01/06/2026
- Etzer Darout from Barclays set a target price of $18.0 on 12/17/2025
- Sudan Loganathan from Stephens & Co. set a target price of $15.0 on 11/10/2025
- Derek Archila from Wells Fargo set a target price of $15.0 on 11/06/2025
- Jeet Mukherjee from BTIG set a target price of $14.0 on 10/30/2025
- Paul Choi from Goldman Sachs set a target price of $6.0 on 10/15/2025
Full Release
NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in four upcoming investor conferences:
- TD Cowen 46th Annual Health Care Conference on Tuesday, March 3. Management will participate in a fireside chat, available here , at 1:10 p.m. ET.
- Leerink Global Healthcare Conference on Monday, March 9. Management will participate in a fireside chat, available here , at 4:20 p.m. ET.
- Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10. Management will participate in a fireside chat, available here , at 11:00 a.m. ET.
- 2026 Jefferies Biotech on the Beach Summit on Wednesday, March 11.
Replays of the fireside chats will be available on the Events and Presentations section of the Company’s website.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X .
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
[email protected]
Media:
Kirsten Owens
+1 (203) 584-0307
[email protected]
